Berardi R R, Cohen I A, Hyneck M L, Lockwood G F, Shukla U A, Sakmar E, Wells J J, Wagner J G
Biopharm Drug Dispos. 1984 Apr-Jun;5(2):169-76. doi: 10.1002/bdd.2510050210.
A two-way crossover bioavailability study of two commercial cimetidine formulations was performed on 24 healthy male volunteers. Drug was administered after an overnight fast and plasma samples were withdrawn periodically for 12 h. Urine was collected throughout the study period. Results indicated that the two formulations were bioequivalent since no statistically significant difference in means was detected for any of the parameters studied. Extensive interpatient variation in cimetidine blood concentration was observed during both treatments.
